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Introduction
Antibody (Ab) targeting of epitopes on folded proteins is a complex immunological process involving many factors (reviewed in El-Manzalawy and Honavar, 2010; Sela-Culang et al., 2013) . Thirty years of experience in the therapeutic Ab pipeline has shown that some epitopes are clearly of higher therapeutic value than others -for instance, those involved in receptor agonism, receptor down-regulation by internalization, or receptor interaction with a soluble ligand (reviewed in Scott et al., 2012) . Isolation of Abs against epitopes of therapeutic interest can be challenging if such Abs are rare and/or of low affinity, and may require extensive screening. Therefore, strategies for isolation of Abs against prespecified epitopes are desirable.
In conjunction with Ab library technology, next-generation DNA sequencing (NGS) can be a powerful tool for 'function-first' discovery of Abs with complex phenotypes (Fischer, 2011; Henry et al., 2015; Ravn et al., 2013) . Here, using a combination of phagedisplay selection and NGS, we present a strategy for isolating singledomain Abs (sdAbs) against pre-specified epitopes on folded proteins, using the cytokine transforming growth factor beta-3 (TGF-β3) as a model target antigen. Specifically, we constructed a phage-displayed sdAb library from the lymphocytes of a llama immunized with TGF-β3 and panned the library in a single round against TGF-β3. We eluted sdAbs competitively with either soluble TGF-β receptor ectodomain (Zwaagstra et al.,2012 ) or an irrelevant competitor, used NGS of panning outputs to identify sdAbs specifically displaced by the former biomolecule, and characterized the resulting sdAbs using binding and in vitro cytokine neutralization assays (Fig. 1) . The TGF-β-neutralizing sdAbs identified here are promising immunotherapeutics in a variety of malignant and fibrotic conditions in which signaling by the pleiotrophic TGF-β cytokine family becomes dysregulated, and offer clear advantages in stability and manufacturability over receptor ectodomain ligand traps.
Materials and Methods

Llama immunization, library construction and panning
A male llama (Lama glama) was immunized five times with 180 µg TGF-β3 (a gift from Andrew Hinck, University of Texas Health Science Center, San Antonio, TX) as previously described (Henry et al., 2015) , except that the antigen was formulated in 100 mM glycine buffer, pH 2.5. Acidic buffered solution was used due to TGF-β3's hydrophobicity and tendency to aggregate at physiological pH (Pellaud et al., 1999) . After the third and fourth immunizations, serum and peripheral blood mononuclear cells (PBMCs) were obtained from the animal. Serum ELISAs were conducted as described in Supplementary Material.
A phage-displayed sdAb library was constructed from the heavychain-only IgG repertoire of the TGF-β3-immunized llama as previously described (Arbabi-Ghahroudi et al., 2009a; Baral et al., 2013; Henry et al., 2015; Hussack et al., 2011) . Briefly, total cellular RNA was extracted from approximately 8 × 10 7 PBMCs using a PureLink ® RNA Mini Kit (Life Technologies, Carlsbad, CA), reverse transcribed using qScript TM cDNA SuperMix (Quanta BioSciences, Gaithersburg, MD) as per the manufacturer's instructions and then pooled. Rearranged and expressed V H H genes were amplified using semi-nested PCR and cloned into the pMED1 phagemid vector, then phage were rescued from library-bearing Escherichia coli TG1 cells by superinfection with M13KO7 helper phage (Life Technologies) and purified by polyethylene glycol precipitation. The phage-displayed sdAb library was panned in a single round against immobilized TGF-β3 as previously described (ArbabiGhahroudi et al., 2009a; Baral et al., 2013; Henry et al., 2015; Hussack et al., 2011) Creative Biolabs, Shirley, NY).
Next-generation DNA sequencing and analysis
Approximately 10 6 library phage particles or phage particles eluted from the single round of panning were used directly as templates for NGS as previously described (Henry et al., 2015) . Indexed amplicon libraries were produced in two rounds of PCR, pooled, purified and then sequenced on a MiSeq Sequencing System (Illumina, San Diego, CA) using a 500-cycle MiSeq Reagent Kit V2 and a 5% PhiX genomic DNA spike. From each sample, 0.3-1.6 million reads were generated, of which 0.1-0.6 million were used for analysis after assembly using FLASH (default parameters; Magoc and Salzberg, 2011) and quality filtering using the FAST-X toolkit with a stringency of Q30 over ≥ 95% of each read (Schmieder and Edwards, 2011; Supplementary Table SI) . The DNA sequence of each sdAb was then translated in silico, and the CDR3 sequence (IMGT positions 105-117) parsed using conserved N-terminal amino acid consensus sequences (YYC).
Expression and characterization of sdAbs
The DNA sequences of seven sdAbs were synthesized commercially in the pSJF2 expression vector (Arbabi-Ghahroudi et al., 2009b; GenScript, Piscataway, NJ) and each construct was expressed in E. coli as previously described (Arbabi-Ghahroudi et al., 2009a; Baral et al.,2 0 1 3 ; Henry et al.,2 0 1 5 ; Hussack et al.,2 0 1 1 ). Briefly, 10 mL 2 × YT starter cultures containing 100 µg/mL ampicillin were inoculated with single plasmid-bearing E. coli TG1 colonies and grown overnight at 37°C with 220 rpm shaking. The next day, 250 mL 2 × YT cultures containing 100 µg/mL ampicillin, 0.1% (w/v) glucose and 0.5 mM IPTG were inoculated with 0.2 mL of starter culture and grown overnight at 37°C with 220 rpm shaking. The next morning, periplasmic proteins were extracted by osmotic shock, dialyzed and purified on a HiTrap IMAC HP column (GE Healthcare, Piscataway, NJ) using an ÄKTA FPLC protein purification system (GE Healthcare) with yields ranging from 1.2 to 14 mg/250 mL. Prior to surface plasmon resonance (SPR), the sdAbs were purified by size exclusion chromatography as previously described (Arbabi-Ghahroudi et al., 2009a; Baral et al., 2013 ) using a Superdex TM 75 10/300 GL column (GE Healthcare) on an ÄKTA FPLC protein purification system (GE Healthcare). To determine the affinities of the sdAbs to TGF-β isoforms (all gifts from A. Hinck), a total of 369-530 resonance units (RUs) of each TGF-β protein were immobilized in 10 mM acetate buffer, pH 4.5, on CM5 sensor chips (GE Healthcare) using an amine coupling kit (GE Healthcare). Steady-state analyses were carried out on a Biacore T200 instrument (GE Healthcare) at 25°C by injecting sdAbs at concentrations ranging from 500 to 4 nM, in HBS-EP + buffer (10 mM HEPES buffer, pH 7.4, containing 150 mM NaCl, 3 mM EDTA and 0.05% (v/v) surfactant P20) and at a flow rate of 50 µL/min. Data were analyzed using Biacore™ T200 Software v3.0 (GE Healthcare) and fitted to a 1:1 binding model. For competition SPR experiments, we immobilized 276 RUs of (TβRII) 2 trap in 10 mM acetate buffer, pH 4.5, on a CM5 sensor chip using an amine coupling kit. Next, either (i) 10 nM of TGF-β3 alone, (ii) 10 nM of TGF-β3 preincubated for 30 min at room temperature with sdAbs (V H H1, V H H3 or V H H6) at concentrations equivalent to 25-fold their K D , or (iii) sdAbs alone at concentrations equivalent to 25-fold their K D , were injected over immobilized (TβRII) 2 trap on a Biacore T200 instrument at 10°C in HBS-EP+ buffer using a flow rate of 50 µL/min. Injections lasted for 20 s, followed by 10 min dissociation.
Results
ELISAs using polyclonal serum IgGs collected from the immunized llama on day 42 showed that: (i) immunization with TGF-β3 elicited serum Abs that bound all three isoforms of TGF-β ( Supplementary  Fig. S1 ) and (ii) a subset of the Abs elicited in response to immunization competed with soluble dimeric type II TGF-β receptor ectodomain [(TβRII) 2 ; Zwaagstra et al., 2012] for TGF-β3 binding, since binding of (TβRII) 2 to TGF-β3 was diminished in the presence of serum from the TGF-β3-immunized llama ( Supplementary Fig. S2 ). These data provided preliminary evidence that Abs (including heavy-chain-only Abs) directed against the site of (TβRII) 2 :TGF-β interaction comprised some proportion of polyclonal serum IgG.
For both pannings (using competitive elution with either (TβRII) 2 or an irrelevant competitor), the set of CDR3 sequences derived from the output phage was compared to the set from the unpanned sdAb library; for each shared CDR3 sequence, an enrichment score was calculated as the frequency in the output phage divided by the frequency in the library. Using these enrichment scores, we identified seven putative epitope-specific sdAbs using two sets of criteria: (i) ≥ 50-fold enrichment of the sdAb in (TβRII) 2 -eluted output phage along with ≤10-fold enrichment in anti-RSV Ab-eluted output phage (V H H1-V H H3), or (ii) largest absolute difference in enrichment scores between (TβRII) 2 and anti-RSV Ab elutions (V H H4-V H H7; Table I ). The rationale for using these two criteria to identify epitope-specific sdAbs was as follows: (i) if epitope-specific sdAbs are infrequent in the library or have slow offrates, then they should be enriched by panning using competitive elution and not enriched by panning using an irrelevant competitor; (ii) if epitope-specific sdAbs are frequent in the library or have fast off-rates, then they may be appreciably enriched even using an irrelevant competitor, and thus the expected signal of competitive replacement would be the magnitude of differences in enrichment scores, comparing elution with epitope-specific competitor to elution with irrelevant competitor. None of the sdAbs were clonally related, as their CDR3 sequences differed in length and shared no sequence homology (Supplementary Table SII) .
We studied the binding of the expressed sdAbs to TGF-β3b y ELISA and SPR. Prior to purification, ELISA was conducted using crude sdAb-containing periplasmic extracts to assess binding to either directly immobilized or (TβRII) 2 trap-captured TGF-β3 ( Fig. 2A) . Six of seven sdAbs bound specifically to immobilized TGF-β3 but two sdAbs (V H H3 and V H H6) did not bind (TβRII) 2 trap-captured TGF-β3, indicating that they may recognize epitopes identical to or overlapping that of the (TβRII) 2 trap; in purified form, these sdAbs also competed with (TβRII) 2 trap for TGF-β3 binding in ELISA ( Supplementary Fig. S3 ). One sdAb, V H H4, did not bind either immobilized or (TβRII) 2 trap-captured TGF-β3. As shown in Table II , the six sdAbs bound TGF-β3 with affinities ranging from 12 to 284 nM; three of the sdAbs (V H H2, V H H3 and V H H6) bound TGF-β2 with slightly weaker affinity but none crossreacted significantly with TGF-β1.
To confirm the epitope specificity of the V H H3 and V H H6 sdAbs, we performed competitive SPR experiments in which mass transport-limited binding of soluble TGF-β3 to immobilized (TβRII) 2 trap was assessed in the presence or absence of excess soluble sdAb. As shown in Fig. 2B-D , V H H3 and V H H6, but not V H H1, clearly inhibited binding of TGF-β3t ot h e( T βRII) 2 trap. In all cases, sdAbs alone did not bind to immobilized (TβRII) 2 trap (green line) and injecting 10 nM of TGF-β3 produced a response of 75 RUs (red line) with little detectable dissociation from the bivalent (TβRII) 2 trap. Preincubation of V H H3 and V H H6, but not V H H1, with TGF-β3 reduced the amount of TGF-β3 available to bind immobilized (TβRII) 2 trap (blue line), indicating that both of these sdAbs are capable of blocking the TGF-β3:(TβRII) 2 interaction. V H H1 bound to immobilized (TβRII) 2 trap as a sdAb-TGF-β3 complex with the sdAb quite rapidly dissociating from the trimolecular complex after the injection. None of > 20 other sdAbs selected for binding to TGF-β3 without regard to epitope specificity competed with (TβRII) 2 trap for TGF-β3 binding ( Supplementary  Fig. S4 ).
Finally, two sdAbs directed against the site of the TGF-β3: (TβRII) 2 interaction (V H H3, V H H6) and two sdAbs directed against other sites (V H H2, V H H5) were expressed by transient transfection of HEK293-6E cells as fusions to human IgG1 F c and hinge region as previously described (Zhang et al., 2009) . The sdAb-F c s were assessed for their ability to neutralize TGF-β1 and TGF-β3 in vitro using IL-11 secretion by TGF-β-sensitive A549 cells as a readout of TGF-β signaling (Rapoza et al., 2006) . V H H3-F c neutralized TGF-β3 most potently in a dose-dependent manner, although all of the V H H-F c s neutralized TGF-β3 at high concentrations (Fig. 3) . Neutralization of TGF-β3 appeared to be primarily affinitydependent (Table II, Fig. 3) . Only V H H3-F c neutralized TGF-β1.
Discussion
High-affinity immune Abs directed against specific epitopes of folded proteins can be difficult to obtain in cases where epitopes are not inherently immunogenic. While alternative strategies for selection of epitope-specific Abs have been described (e.g., de novo protein design (Sormanni et al., 2015) ; screening of naïve or synthetic sources of Ab diversity (Sidhu and Fellouse, 2006) ; recombinant protein scaffolds bearing 'grafted' exogenous epitopes as immunization or screening reagents (Burton, 2010) ), these can be laborious and often result in Abs that are deficient in affinity or other properties. For therapeutic Abs against well-characterized targets, epitopes of functional importance are sometimes known and thus the ability to select Abs for desired epitope specificity during early stages of development is a major advantage. Calculated from a single concentration injection. 10 pM TGF-β1o rT GF-β3 was preincubated in complete media with the indicated concentrations of sdAb-F c so r( T βRII) 2 trap for 30 min at room temperature, then the mixture was added to cells for 18 h at 37°C. Aliquots of conditioned media were added to MSD ® S t r e p t a v i d i nG o l dp l a t e s( M e s o Scale Diagnostics, Gaithersburg, MD) coated with 2 μg/mL biotinylated mouse anti-human IL-11 antibody (MAB618, R&D Systems, Minneapolis, MN) for 18 h at room temperature, washed with PBS containing 0.05% Tween-20, treated with 2 μg/mL SULFO-tagged goat anti-human IL-11 antibody (AF-218-NA, R&D Systems) for 1 h at RT. After a final wash, plates were read on a MESO QuickPlex SQ 120 imager (Meso Scale Diagnostics). The results were normalized to cell numbers/well (CyQUANT®, Thermo Fisher) and expressed as % IL-11 release compared to control cells treated with TGF-β1orTGF-β3 alone. Using a single round of panning and NGS analysis, we were able to isolate two sdAbs that competed with soluble dimeric type II TGF-β receptor ectodomain for TGF-β3 binding. Neither panning of the same phage-displayed sdAb library against TGF-β3 with nonspecific elution of sdAbs using triethylamine ( Supplementary Fig.  S4 ), nor direct screening of Ab-secreting cells for binding to any TGF-β3 epitope (data not shown), yielded sdAbs against this site. We speculate that since the expression yields and binding affinities of the two sdAbs against this site were not unusual, failure to recover them through conventional panning approaches may instead relate to their frequencies in the library (in comparison to non-site-specific sdAbs), as well as to peculiarities of their epitope (e.g., conformational lability; potential steric hindrance of sdAb-phage binding to this site).
The principle underlying this strategy (competitive replacement of sdAb-bearing phage by a protein interacting with the same site) has several implications for the types of Abs we expect to recover and the circumstances under which it will be successful. First, competitive replacement can be a very weak force of selection, depending on the binding affinities and kinetics as well as the relative concentrations of the competitor and phage-displayed sdAb; here, we used high concentrations of bivalent (TβRII) 2 trap (subnanomolar apparent affinity for TGF-β3) to maximize the signal of competitive replacement. However, epitope-specific sdAbs did not rise to high frequency even after multiple panning rounds with the high-affinity competitor used here (data not shown), necessitating comparative approaches using NGS. Second, the selection is primarily off-rate dependent, and epitope-specific sdAbs with faster offrates will be easier to detect using this method. Since sdAb-bearing phage, regardless of epitope specificity, will dissociate from immobilized antigen regardless of the presence or absence of a competitor, comparison of the relative amounts of sdAb-phage eluted using site-specific and irrelevant competitors is critical. Third, since competition approaches are inextricably linked to the sizes of the competing molecules, competitive binding of sdAb-phage may not accurately predict the behavior of soluble sdAbs or sdAb-F c s. Finally, binding of the competitor may under some circumstances induce conformational changes at a distance from the site of interaction, displacing sdAb-phage directed elsewhere on the antigen. Thus, some degree of type I error may be unavoidable, but in our hands this strategy has reliably yielded epitope-specific sdAbs against several targets if these are present in the library (data not shown).
There are several limitations and caveats to the work presented here. First, we present only one case study of a single antigen and epitope of interest, and the results may vary substantially depending on properties of the antigen, the Abs present in the library and the competitor used. Second, this strategy is valid only for epitopes against which Abs or other affinity reagents such as receptor ectodomains are available. Third, in many cases this strategy may be unnecessary, as traditional panning of phage-displayed libraries with non-specifice l ution of all binding Abs may yield Abs directed against the desired epitope without any special effort. Finally, the necessity of targeting specific epitopes depends largely on the application, as shown here: the epitope specificity of sdAb monomers turned out to be largely irrelevant to their neutralization potency as sdAb-F c fusions, presumably due to the larger size of the latter molecules.
In summary, we report a strategy for rapid identification of sdAbs to pre-specified epitopes on folded proteins, using TGF-β3 as a model antigen. Using a single round of panning in the presence or absence of an epitope-specific competitor followed by NGS, we identified two TGF-β3-specific sdAbs capable of blocking the interaction between TGF-β3 and its cell-surface receptor and neutralizing TGF-β3 in cell-based assays. The sdAbs isolated here are being developed as immunotherapeutics for TGF-β-driven diseases including cancer and fibrosis (Hawinkels and Ten Dijke, 2011) . More generally, panning of phage-displayed Ab libraries with competitive elution followed by NGS can be a useful tool for discovery of biobetter Abs.
Supplementary data
Supplementary data are available at PEDS online.
